Nicotinamide Mononucleotide

DIETARY_SUPPLEMENT7 trials

Sponsors

Seneque SA, Abinopharm, Inc, Vedic Lifesciences Pvt. Ltd., Haukeland University Hospital, The Third Xiangya Hospital of Central South University

Conditions

AgingCOVID-19 InfectionGlaucomaHealthyHuman Immunodeficiency VirusMuscle RecoveryPhysical ActivityUlcerative Colitis Chronic Mild

Phase 1

NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy

CompletedNCT05698771

Haukeland University HospitalHealthy

Start: 2022-09-17End: 2024-03-04Updated: 2025-01-17

Phase 2

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

RecruitingNCT06991712

Christopher Kai Shun LeungGlaucoma

Start: 2025-05-19End: 2026-12-31Target: 138Updated: 2025-06-26

Unknown Phase

Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity

CompletedNCT04664361

Seneque SAMuscle Recovery, Physical Activity

Start: 2021-03-09End: 2023-05-30Updated: 2024-01-17

To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults

CompletedNCT04823260

Abinopharm, IncAging

Start: 2021-05-25End: 2021-09-09Updated: 2021-10-01

Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection

TerminatedNCT05175768

Vedic Lifesciences Pvt. Ltd.COVID-19 Infection

Start: 2021-12-27End: 2022-07-16Updated: 2024-09-23

Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

RecruitingNCT06214078

The Third Xiangya Hospital of Central South UniversityUlcerative Colitis Chronic Mild

Start: 2024-02-01End: 2025-07-30Target: 48Updated: 2024-01-19

Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure

Not yet recruitingNCT06889142

TriHealth Inc.Human Immunodeficiency Virus

Start: 2025-04-30End: 2025-07-31Target: 7Updated: 2025-04-03

Related Papers

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease

Alzheimer s Research & Therapy2025-03-117 citations

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

GeroScience2022-12-08132 citations

A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults

Frontiers in Aging2022-05-0553 citations